npj Breast Cancer (Jun 2024)

Targeting fatty acid synthase in preclinical models of TNBC brain metastases synergizes with SN-38 and impairs invasion

  • Habib A. Serhan,
  • Liwei Bao,
  • Xu Cheng,
  • Zhaoping Qin,
  • Chia-Jen Liu,
  • Jason A. Heth,
  • Aaron M. Udager,
  • Matthew B. Soellner,
  • Sofia D. Merajver,
  • Aki Morikawa,
  • Nathan M. Merrill

DOI
https://doi.org/10.1038/s41523-024-00656-0
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Fatty acid synthesis (FAS) has been shown to play a key role in the survival of brain-metastatic (BM) breast cancer. We demonstrate that the fatty acid synthase inhibitor TVB-2640 synergizes with the topoisomerase inhibitor SN-38 in triple-negative breast cancer (TNBC) BM cell lines, upregulates FAS and downregulates cell cycle progression gene expression, and slows the motility of TNBC BM cell lines. The combination of SN-38 and TVB-2640 warrants further consideration as a potential therapeutic option in TNBC BMs.